Developer docs
API playgroundTry for free, no card

Search company profiles

PhaseV

Full company profile

uuid00003gz

Namestring
PhaseV
Legal namestring
PhaseV
Company typeenum
Private
Founded yearint
2023
Descriptiontext

PhaseV is a privately held, AI-native clinical development technology company founded in 2023 and headquartered in Cambridge, Massachusetts, with an engineering and R&D office in Tel Aviv, Israel. The company sells an end-to-end AI/ML platform to global biopharma sponsors and contract research organizations, organized as four core modules — Trial Optimizer (Bayesian and adaptive trial design simulation), Response Optimizer (causal ML for heterogeneous treatment effect and responder subgroup detection), Portfolio Optimizer (causal disease modeling for biomarker and indication strategy), and ClinOps Optimizer (causal ML-driven site selection and trial operations) — plus a 10M+ patient-level DataLake, the recently launched AI Conductor protocol-to-submission automation platform (March 2026), and an AI-Powered Enrollment Lab (February 2026).

The platform's underlying technology combines Bayesian statistics, causal machine learning, GenAI, and reinforcement learning, applied across structured clinical trial and real-world patient-level data with proprietary methods such as Causal Responder Detection (CARD), Robust CATE ensemble estimation, ML Early-Derived Endpoint Identification, and Hidden Markov Model-based RWD cleaning. PhaseV is cloud-native on AWS and holds ISO 27001, GDPR, HIPAA, and CCPA certifications.

PhaseV operates a hybrid revenue model combining per-project tech-enabled services (professional services delivered by in-house ML, data science, clinical, and medical experts) with optional recurring SaaS subscriptions to individual platform modules, sold under multi-year enterprise contracts. Distribution runs through direct enterprise sales (Book a Demo CTAs), a growing CRO channel (Quanticate, Bioforum, iOMEDICO, Alimentiv), marketplace listings (9xchange Biopharma), and co-development partnerships with foundations such as the Crohn's & Colitis Foundation. As of late 2025 the company reported 45+ biopharma and CRO customers including at least 7 big pharma, with 2025 revenues described as nearly quintupling year-over-year.

Short descriptiontext

PhaseV provides an AI/ML platform for clinical trial design and operations, serving global biopharma sponsors and CROs. Its modules use causal ML and Bayesian statistics to optimize trial design, identify responder subgroups, model disease biology, and select clinical sites.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial optimization, AI clinical development, adaptive trial design, causal machine learning, biopharma analytics
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAO
Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Custom Computer Programming Services541511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design Services541512
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Clinical Trial Optimization Software
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Tech-Enabled Services (Professional Services)
TypeProfessional Services
Description

Project-based engagements where sponsors/CROs contract PhaseV to deliver tech-enabled services. Scope, timelines and cost defined per project with a dedicated team of ML, data-science, clinical and medical experts providing white-glove service throughout the project.

phasevtrials.com
2Software as a Service (SaaS) Subscription
TypeSubscription Recurring
Description

Recurring subscriptions to one or more PhaseV platform modules (Trial Optimizer, Response Optimizer, Portfolio Optimizer, ClinOps Optimizer) for self-serve use, with ongoing troubleshooting support and customization. Cloud-native on AWS and compatible with most EDC systems.

phasevtrials.com
Marketing channels11 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Per-project Tech-Enabled Services with optional subscription layering
ModelOtherBilling cadenceMulti-year contract
Notes

Scope, timelines and cost defined per project; SaaS subscriptions available on one or more platform modules; cloud-native on AWS; EDC-compatible. No public price points.

phasevtrials.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1Trial Optimizer
Description

AI/ML platform module that runs millions of adaptive, Bayesian, and fixed trial design simulations to optimize sample size, cost, and probability of success.

phasevtrials.com
+5 more records
Core offering1 text field

PhaseV provides an AI/ML-driven platform that helps biopharma sponsors and CROs design, optimize, and execute clinical trials more efficiently. The platform combines causal machine learning, Bayesian adaptive design, GenAI, and reinforcement learning on top of a 10M+ patient data lake to support trial simulation, heterogeneous treatment effect analysis, biomarker-driven portfolio decisions, and ML-driven site selection. Offerings are delivered as multi-module SaaS subscriptions (Trial Optimizer, Response Optimizer, Portfolio Optimizer, ClinOps Optimizer, AI Conductor) plus project-based tech-enabled services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Up to 50% reduction in trial costs
+6 more records
Product overview1 text field

PhaseV offers a unified multi-modal AI/ML platform for end-to-end clinical development, structured as a platform-plus-modules architecture that seamlessly bridges retrospective data analysis with trial design and execution. The core platform consists of four primary modules — Trial Optimizer (AI-driven trial design simulation and optimization), Response Optimizer (causal ML for heterogeneous treatment effect detection and subgroup identification), Portfolio Optimizer (causal disease modeling for biomarker analysis and indication selection), and ClinOps Optimizer (causal ML-driven site selection and real-time trial operations analytics). These modules are powered by the PhaseV DataLake, a proprietary data infrastructure containing 10M+ patient-level records, and are augmented by the AI Conductor centralized automation platform, the AI-Powered Enrollment Lab, and ML Early-Derived Endpoint Identification capabilities. Together, these offerings support biopharma sponsors and CROs across the full clinical development lifecycle, including trial design, patient stratification, site selection, asset evaluation, indication sequencing, and regulatory submission.

Product and service7 records
1Trial Optimizer
CategoryCore platform module
Description

AI/ML-powered module that runs millions of adaptive, Bayesian, and fixed trial design simulations within minutes, optimizing sample size and cost across Phase 1-3 studies including BOIN12, Seamless 2/3, and Response-Adaptive Randomization designs. Built for biopharma sponsors and CROs seeking faster, leaner trial protocols.

2Response Optimizer
CategoryCore platform module
Description

Causal machine learning module that detects heterogeneous treatment effects across covariates, identifies optimal responder subgroups and biomarkers, and supports trial rescue by pinpointing patients most likely to benefit from therapy. Built on PhaseV's published CARD (Causal Responder Detection) and Robust CATE ensemble methods.

3Portfolio Optimizer
CategoryCore platform module
Description

Causal disease modeling module that builds directed acyclic graphs (DAGs) from biomarkers and real-world data to quantify biomarker impact on clinical outcomes, identify key pathways and mediators, and run what-if scenario simulations for combination therapy assessment and indication expansion.

4ClinOps Optimizer
CategoryCore platform module
Description

Clinical operations module using causal machine learning for precision-guided site selection aligned with drug mechanism of action and patient heterogeneity, real-time enrollment and dropout tracking, patient progression analytics, and virtual control arm support.

5AI Conductor
CategoryPlatform orchestration product
Description

Centralized AI-powered platform launched in March 2026 that automates end-to-end protocol-to-submission clinical trial workflows, integrating regulatory compliance, data management, and collaboration features to reduce trial costs and improve success rates. Aimed at biopharma sponsors and CROs.

6AI-Powered Enrollment Lab
CategoryEnrollment optimization module
Description

Solution launched at the 17th Annual SCOPE Summit in February 2026 that uses real-world data and AI/ML to help sponsors assess and optimize clinical trial enrollment potential and feasibility before protocol lock.

7Tech-Enabled Services (Professional Services)
CategoryProfessional services
Description

Project-based engagements where sponsors and CROs contract PhaseV to deliver tech-enabled services with a dedicated team of ML, data-science, clinical and medical experts providing white-glove service throughout the project, layered on top of the SaaS modules.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCharitable Sponsorship PartnerTypeOthersAnnounced on2026-04-01
Description

PhaseV sponsored the Timmerman Traverse at 'Mt. Emerson' level and pledged 5% of net revenues from all new oncology-related work in Q2 2026 to the foundation. Hamza Sheikh, PhaseV's VP of Business and Corporate Development, represented PhaseV on the trek. The Traverse has raised more than $3M for the foundation since 2023.

Strategic tierFlagship Cro Channel PartnerTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-01
Description

Bioforum became the latest CRO to deploy PhaseV's AI trial design technology (per BioXconomy, Sept 2025); PhaseV and Bioforum announced a partnership to enhance clinical trials with AI/ML (per Clinical Trials Arena and Yahoo Finance).

Strategic tierStrategic Data / Disease-Area PartnerTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Partnership to fast-track IBD clinical trials with AI; integrates data from the Foundation's IBD Plexus® with PhaseV's causal ML platform for site selection and trial execution.

Strategic tierStrategic Co-Development Partner (Gi)TypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Partnership to support execution of adaptive clinical trials for GI; Alimentiv (GI-focused CRO) is integrating PhaseV's adaptive machine learning software with its GI therapeutic expertise.

Strategic tierAcademic Co-Development PartnerTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Co-development agreement to advance machine learning-driven lupus research; part of DDW's 'Seven new drug discovery deals powered by AI' coverage (January 2025).

Strategic tierFlagship Cro Channel PartnerTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-01
Description

Partnership to deliver a new adaptive clinical trial service to sponsors; Quanticate is a PhaseV CRO channel partner helping sponsors run more adaptive trials using PhaseV's platform.

Strategic tierStrategic Co-Development Partner (Oncology)TypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

PhaseV and iOMEDICO partnered to launch a new ML-powered solution to increase success rates of Phase 3 oncology trials, combining causal inference with rich oncology real-world data for advanced covariate adjustment.

89xchange Biopharma Marketplace
Strategic tierEcosystem Distribution PartnerTypeGTM or Marketing PartnerAnnounced on2023-11-01
Description

Partnership to bring PhaseV's ML-powered clinical trial optimization technology to 9xchange ecosystem members; featured in PharmaShots interview with CEO Raviv Pryluk.

phasevtrials.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest clinical trial technology platform (Rave EDC, RTSM, eCOA) used by most major sponsors. Direct adjacency to PhaseV in trial design/operations, but as part of a much broader CRO-aligned software suite rather than a focused AI-native offering.

TypeBroad incumbent
Description

Enterprise cloud software for life sciences, including Veeva Vault Clinical Suite used by global biopharma for trial operations. Adjacent buyer base and overlapping workflows, though Veeva is broader than trial design AI.

TypeBroad incumbent
Description

Incumbent EDC/CTMS vendor with a large installed base among biopharma sponsors; increasingly embedding analytics and AI features, competing for the same enterprise budget as PhaseV.

TypeDirect peer
Description

Specialist in adaptive trial design, Bayesian statistics, and clinical trial software (East®) — directly comparable expertise to PhaseV's Trial Optimizer and adaptive-trial capabilities.

TypeEmerging player
Description

AI platform for oncology real-world data and clinical trial optimization; competes with PhaseV's Response Optimizer and Portfolio Optimizer for biopharma AI budgets in oncology.

TypeEmerging player
Description

AI biotech applying ML to patient stratification and trial design for biopharma; partial overlap with PhaseV's HTE/subgroup identification capabilities.

TypeEmerging player
Description

Oncology-specific real-world data and clinical trial technology company; comparable in combining curated clinical data with biopharma trial enablement, focused on oncology vs PhaseV's TA-agnostic approach.

TypeDirect peer
Description

AI-driven clinical trial analytics and data management platform for biopharma; comparable buyer base and overlapping use cases in trial operations and analytics.

TypeBroad incumbent
Description

Largest CRO with deep data assets and proprietary technology platforms touching nearly every sponsor; competes for the same enterprise budget and increasingly layers in AI-driven trial design and analytics.

TypeEmerging player
Description

AI platform for clinical trial feasibility, site selection, and protocol design; comparable in applying ML to clinical operations optimization, particularly for sponsor-side decisioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PhaseV

Clinical Trial Optimization Softwarephasevtrials.com

PhaseV provides an AI/ML platform for clinical trial design and operations, serving global biopharma sponsors and CROs. Its modules use causal ML and Bayesian statistics to optimize trial design, identify responder subgroups, model disease biology, and select clinical sites.

What PhaseV does

PhaseV is a privately held, AI-native clinical development technology company founded in 2023 and headquartered in Cambridge, Massachusetts, with an engineering and R&D office in Tel Aviv, Israel. The company sells an end-to-end AI/ML platform to global biopharma sponsors and contract research organizations, organized as four core modules — Trial Optimizer (Bayesian and adaptive trial design simulation), Response Optimizer (causal ML for heterogeneous treatment effect and responder subgroup detection), Portfolio Optimizer (causal disease modeling for biomarker and indication strategy), and ClinOps Optimizer (causal ML-driven site selection and trial operations) — plus a 10M+ patient-level DataLake, the recently launched AI Conductor protocol-to-submission automation platform (March 2026), and an AI-Powered Enrollment Lab (February 2026).

The platform's underlying technology combines Bayesian statistics, causal machine learning, GenAI, and reinforcement learning, applied across structured clinical trial and real-world patient-level data with proprietary methods such as Causal Responder Detection (CARD), Robust CATE ensemble estimation, ML Early-Derived Endpoint Identification, and Hidden Markov Model-based RWD cleaning. PhaseV is cloud-native on AWS and holds ISO 27001, GDPR, HIPAA, and CCPA certifications.

PhaseV operates a hybrid revenue model combining per-project tech-enabled services (professional services delivered by in-house ML, data science, clinical, and medical experts) with optional recurring SaaS subscriptions to individual platform modules, sold under multi-year enterprise contracts. Distribution runs through direct enterprise sales (Book a Demo CTAs), a growing CRO channel (Quanticate, Bioforum, iOMEDICO, Alimentiv), marketplace listings (9xchange Biopharma), and co-development partnerships with foundations such as the Crohn's & Colitis Foundation. As of late 2025 the company reported 45+ biopharma and CRO customers including at least 7 big pharma, with 2025 revenues described as nearly quintupling year-over-year.

PhaseV firmographics

Firmographics
Name
PhaseV
Legal name
PhaseV
Website
https://phasevtrials.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
PhaseV provides an AI/ML platform for clinical trial design and operations, serving global biopharma sponsors and CROs. Its modules use causal ML and Bayesian statistics to optimize trial design, identify responder subgroups, model disease biology, and select clinical sites.
Ownership category
akta.pro rank

PhaseV industry classification

Industry
Product category
Clinical Trial Optimization Software
NAICS
Custom Computer Programming Services (541511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design Services (541512)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAO
Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Clinical trial optimization
  • AI clinical development
  • Adaptive trial design
  • Causal machine learning
  • Biopharma analytics

Where PhaseV is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

PhaseV business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Tech-Enabled Services (Professional Services): Project-based engagements where sponsors/CROs contract PhaseV to deliver tech-enabled services. Scope, timelines and cost defined per project with a dedicated team of ML, data-science, clinical and medical experts providing white-glove service throughout the project.
  2. Software as a Service (SaaS) Subscription: Recurring subscriptions to one or more PhaseV platform modules (Trial Optimizer, Response Optimizer, Portfolio Optimizer, ClinOps Optimizer) for self-serve use, with ongoing troubleshooting support and customization. Cloud-native on AWS and compatible with most EDC systems.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPer-project Tech-Enabled Services with optional subscription layering

Go-to-market motion3 records

Distribution channels5 records

Marketing channels11 records

PhaseV product offering

Product offering

Core offering

PhaseV provides an AI/ML-driven platform that helps biopharma sponsors and CROs design, optimize, and execute clinical trials more efficiently. The platform combines causal machine learning, Bayesian adaptive design, GenAI, and reinforcement learning on top of a 10M+ patient data lake to support trial simulation, heterogeneous treatment effect analysis, biomarker-driven portfolio decisions, and ML-driven site selection. Offerings are delivered as multi-module SaaS subscriptions (Trial Optimizer, Response Optimizer, Portfolio Optimizer, ClinOps Optimizer, AI Conductor) plus project-based tech-enabled services.

Product overview

PhaseV offers a unified multi-modal AI/ML platform for end-to-end clinical development, structured as a platform-plus-modules architecture that seamlessly bridges retrospective data analysis with trial design and execution. The core platform consists of four primary modules — Trial Optimizer (AI-driven trial design simulation and optimization), Response Optimizer (causal ML for heterogeneous treatment effect detection and subgroup identification), Portfolio Optimizer (causal disease modeling for biomarker analysis and indication selection), and ClinOps Optimizer (causal ML-driven site selection and real-time trial operations analytics). These modules are powered by the PhaseV DataLake, a proprietary data infrastructure containing 10M+ patient-level records, and are augmented by the AI Conductor centralized automation platform, the AI-Powered Enrollment Lab, and ML Early-Derived Endpoint Identification capabilities. Together, these offerings support biopharma sponsors and CROs across the full clinical development lifecycle, including trial design, patient stratification, site selection, asset evaluation, indication sequencing, and regulatory submission.

Differentiator

Problem solved

Functional benefit

Brands

  • Trial Optimizer: AI/ML platform module that runs millions of adaptive, Bayesian, and fixed trial design simulations to optimize sample size, cost, and probability of success.
  • Response Optimizer
  • Portfolio Optimizer
  • ClinOps Optimizer
  • AI Conductor
  • AI-Powered Enrollment Lab

Products and services

  • Trial Optimizer AI/ML-powered module that runs millions of adaptive, Bayesian, and fixed trial design simulations within minutes, optimizing sample size and cost across Phase 1-3 studies including BOIN12, Seamless 2/3, and Response-Adaptive Randomization designs. Built for biopharma sponsors and CROs seeking faster, leaner trial protocols.
  • Response Optimizer Causal machine learning module that detects heterogeneous treatment effects across covariates, identifies optimal responder subgroups and biomarkers, and supports trial rescue by pinpointing patients most likely to benefit from therapy. Built on PhaseV's published CARD (Causal Responder Detection) and Robust CATE ensemble methods.
  • Portfolio Optimizer Causal disease modeling module that builds directed acyclic graphs (DAGs) from biomarkers and real-world data to quantify biomarker impact on clinical outcomes, identify key pathways and mediators, and run what-if scenario simulations for combination therapy assessment and indication expansion.
  • ClinOps Optimizer Clinical operations module using causal machine learning for precision-guided site selection aligned with drug mechanism of action and patient heterogeneity, real-time enrollment and dropout tracking, patient progression analytics, and virtual control arm support.
  • AI Conductor Centralized AI-powered platform launched in March 2026 that automates end-to-end protocol-to-submission clinical trial workflows, integrating regulatory compliance, data management, and collaboration features to reduce trial costs and improve success rates. Aimed at biopharma sponsors and CROs.
  • AI-Powered Enrollment Lab Solution launched at the 17th Annual SCOPE Summit in February 2026 that uses real-world data and AI/ML to help sponsors assess and optimize clinical trial enrollment potential and feasibility before protocol lock.
  • Tech-Enabled Services (Professional Services) Project-based engagements where sponsors and CROs contract PhaseV to deliver tech-enabled services with a dedicated team of ML, data-science, clinical and medical experts providing white-glove service throughout the project, layered on top of the SaaS modules.

Quantifiable outcome

  • Up to 50% reduction in trial costs
  • +6 more outcomes

Companies that use PhaseV

Customer profile

Named customers14 records

Segments5 records

Ideal customer profiles2 records

PhaseV technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature11 records

PhaseV partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered charitable sponsorship partner, flagship cro channel partner, strategic data / disease-area partner, strategic co-development partner (gi), academic co-development partner, strategic co-development partner (oncology) and ecosystem distribution partner.

  • Damon Runyon Cancer Research Foundationcharitable sponsorship partnerOthers · 1 April 2026PhaseV sponsored the Timmerman Traverse at 'Mt. Emerson' level and pledged 5% of net revenues from all new oncology-related work in Q2 2026 to the foundation. Hamza Sheikh, PhaseV's VP of Business and Corporate Development, represented PhaseV on the trek. The Traverse has raised more than $3M for the foundation since 2023.
  • Bioforumflagship cro channel partnerChannel Partner/ Reseller/ Distributor · 1 September 2025Bioforum became the latest CRO to deploy PhaseV's AI trial design technology (per BioXconomy, Sept 2025); PhaseV and Bioforum announced a partnership to enhance clinical trials with AI/ML (per Clinical Trials Arena and Yahoo Finance).
  • Crohn's & Colitis Foundationstrategic data / disease-area partnerStrategic or Co-development Partner · 1 May 2025Partnership to fast-track IBD clinical trials with AI; integrates data from the Foundation's IBD Plexus® with PhaseV's causal ML platform for site selection and trial execution.
  • Alimentivstrategic co-development partner (gi)Strategic or Co-development Partner · 1 February 2025Partnership to support execution of adaptive clinical trials for GI; Alimentiv (GI-focused CRO) is integrating PhaseV's adaptive machine learning software with its GI therapeutic expertise.
  • University Health Network (Toronto)academic co-development partnerStrategic or Co-development Partner · 1 January 2025Co-development agreement to advance machine learning-driven lupus research; part of DDW's 'Seven new drug discovery deals powered by AI' coverage (January 2025).
  • Quanticateflagship cro channel partnerChannel Partner/ Reseller/ Distributor · 1 April 2024Partnership to deliver a new adaptive clinical trial service to sponsors; Quanticate is a PhaseV CRO channel partner helping sponsors run more adaptive trials using PhaseV's platform.
  • iOMEDICOstrategic co-development partner (oncology)Strategic or Co-development Partner · 1 March 2024PhaseV and iOMEDICO partnered to launch a new ML-powered solution to increase success rates of Phase 3 oncology trials, combining causal inference with rich oncology real-world data for advanced covariate adjustment.
  • 9xchange Biopharma Marketplaceecosystem distribution partnerGTM or Marketing Partner · 1 November 2023Partnership to bring PhaseV's ML-powered clinical trial optimization technology to 9xchange ecosystem members; featured in PharmaShots interview with CEO Raviv Pryluk.

Scale indicators14 records

Recent moves8 records

Expansion highlights6 records

PhaseV competitors and assessment

Company assessment

Broad incumbents

  • Medidata (Dassault Systèmes): Largest clinical trial technology platform (Rave EDC, RTSM, eCOA) used by most major sponsors. Direct adjacency to PhaseV in trial design/operations, but as part of a much broader CRO-aligned software suite rather than a focused AI-native offering.
  • Veeva Systems: Enterprise cloud software for life sciences, including Veeva Vault Clinical Suite used by global biopharma for trial operations. Adjacent buyer base and overlapping workflows, though Veeva is broader than trial design AI.
  • Oracle Health Sciences (Clinical One / Siebel CTMS): Incumbent EDC/CTMS vendor with a large installed base among biopharma sponsors; increasingly embedding analytics and AI features, competing for the same enterprise budget as PhaseV.
  • IQVIA: Largest CRO with deep data assets and proprietary technology platforms touching nearly every sponsor; competes for the same enterprise budget and increasingly layers in AI-driven trial design and analytics.

Direct peers

  • Cytel: Specialist in adaptive trial design, Bayesian statistics, and clinical trial software (East®) — directly comparable expertise to PhaseV's Trial Optimizer and adaptive-trial capabilities.
  • Saama Technologies: AI-driven clinical trial analytics and data management platform for biopharma; comparable buyer base and overlapping use cases in trial operations and analytics.

Emerging players

  • ConcertAI: AI platform for oncology real-world data and clinical trial optimization; competes with PhaseV's Response Optimizer and Portfolio Optimizer for biopharma AI budgets in oncology.
  • Owkin: AI biotech applying ML to patient stratification and trial design for biopharma; partial overlap with PhaseV's HTE/subgroup identification capabilities.
  • Flatiron Health: Oncology-specific real-world data and clinical trial technology company; comparable in combining curated clinical data with biopharma trial enablement, focused on oncology vs PhaseV's TA-agnostic approach.
  • Trial Library / Mendel (rebrand candidates): AI platform for clinical trial feasibility, site selection, and protocol design; comparable in applying ML to clinical operations optimization, particularly for sponsor-side decisioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

PhaseV social profiles

Digital presence

PhaseV compliance and trust

Trust signal

Compliance4 records

PhaseV financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PhaseV leadership team

Management profile

Number of profiles

Profiles12 records

PhaseV funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PhaseV M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PhaseV

What does PhaseV do?

PhaseV provides an AI/ML-driven platform that helps biopharma sponsors and CROs design, optimize, and execute clinical trials more efficiently. The platform combines causal machine learning, Bayesian adaptive design, GenAI, and reinforcement learning on top of a 10M+ patient data lake to support trial simulation, heterogeneous treatment effect analysis, biomarker-driven portfolio decisions, and ML-driven site selection. Offerings are delivered as multi-module SaaS subscriptions (Trial Optimizer, Response Optimizer, Portfolio Optimizer, ClinOps Optimizer, AI Conductor) plus project-based tech-enabled services.

Is PhaseV a public or private company?

PhaseV is a private company. It is classified as venture growth investor backed and is currently operating.

When was PhaseV founded?

PhaseV was founded in 2023. It employs 51 to 100 people.

Where is PhaseV based?

PhaseV is headquartered in Cambridge, United States, in the North America region.

How does PhaseV make money?

Two revenue lines are on record. Tech-Enabled Services (Professional Services) is the primary driver. The others are software as a Service (SaaS) Subscription.

Who are PhaseV's main competitors?

Broad incumbents on record are Medidata (Dassault Systèmes), Veeva Systems, Oracle Health Sciences (Clinical One / Siebel CTMS) and IQVIA. Direct peers are Cytel and Saama Technologies. Emerging players are ConcertAI, Owkin, Flatiron Health and Trial Library / Mendel (rebrand candidates).

Does PhaseV have an API?

No public API is recorded for PhaseV.

What industry is PhaseV in?

PhaseV's product category is Clinical Trial Optimization Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLACAOAO, Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines). Its NAICS code is 541511 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePhaseV Launches BonV, an Agentic AI Orchestrator Turning Clinical Questions into Defensible DecisionsPhaseV launched BonV, an agentic AI orchestrator that turns clinical questions into documented, evidence-backed trial decisions. In one trial, it orchestrated four modules to cut trial costs by $32 million and shorten duration by eight months. The product is already in use with select pharmaceutical companies, with a phased rollout underway.PR NewswirePhaseV Validates GLP-1 Adverse Event Model on MarketScan and Veradigm Real-World Patient DataPhaseV validated a causal model predicting adverse events, weight trajectory, and dropout for GLP-1 patients using MarketScan and Veradigm data. The model's predictions matched real patient outcomes, offering sponsors evidence-based dosing strategies. PhaseV plans to expand validated evidence across more therapeutic areas.citybizPhaseV Adds Klaus Beck and Avi Kulkarni to Scientific Advisory BoardPhaseV appointed Klaus Beck and Avi Kulkarni to its Scientific Advisory Board to advise on its AI Conductor platform for clinical development workflows. The platform aims to connect fragmented trial components, and PhaseV reports helping customers reduce development costs by up to 50% and shorten trials by up to 40%.EIN PresswireAI-Based Clinical Trials Solution Providers Market Grows at 22.1% CAGR Through 2033 | Persistence Market ResearchThe global AI-based clinical trials solution providers market is projected to grow from US$3.4 billion in 2026 to US$13.9 billion by 2033, a 22.1% CAGR. North America holds about 40% of the market, with oncological disorders accounting for roughly 40% of revenue in 2026. Recent developments include Mass General Brigham's AIwithCare and PhaseV's ClinOps AI platform.Clinical Trials ArenaWave of AI and data science tools set to transform clinical trialsAn interview with Ittai Harel, managing partner at Pitango Venture Capital, previewed a session at the upcoming Biomed Israel conference (May 12-14, 2026) focused on how AI and data science tools are beginning to transform the clinical trial sector, which sees at least $100 billion spent annually with high failure rates. Harel highlighted companies including QuantHealth, PhaseV, ImmunAI, and NeuraLight as promising innovators using artificial intelligence, predictive modeling, and biomarker analysis to improve patient recruitment, trial design, and drug response prediction. He noted that while pharma has been conservative in adopting new technologies, the industry is reaching a tipping point where AI-driven solutions could significantly reduce drug development costs and enable more personalized medicines.PR NewswirePhaseV Sponsors Timmerman Traverse in Support of the Damon Runyon Cancer Research FoundationPhaseV, a Boston-based AI/ML company for clinical development, announced its 'Mt. Emerson' level sponsorship of the Timmerman Traverse, a multi-day biotech industry expedition across California's High Sierras, to raise funds for the Damon Runyon Cancer Research Foundation. The company is also pledging 5% of net revenues from all new oncology-related work in Q2 2026 to the foundation, with Hamza Sheikh, VP of Business and Corporate Development, representing PhaseV on the trek. Since 2023, the Timmerman Traverse has raised more than $3 million for the foundation, which supports young cancer researchers.PR NewswirePhaseV Bringing Integrated AI for Faster Clinical Trials to the Global StagePhaseV, a Boston-based AI/ML company for clinical development, announced its spring and summer 2026 conference schedule, during which leadership will demonstrate how the integration of Bayesian statistics and Causal AI/ML optimizes clinical trial design and execution. The company claims its platform has delivered significant ROI for over 45 pharma and biotech sponsors, reducing trial costs by up to 50% and increasing probability of success by over 30%. PhaseV will present at multiple industry events including BioMed Israel, EULAR 2026 in London, and BIO International in San Diego.PR NewswirePhaseV Launches AI Conductor to Automate Protocol-to-Submission Clinical WorkflowsPhaseV, a Boston-based AI/ML company for clinical development, announced the launch of AI Conductor, a centralized platform that automates the entire clinical trial workflow from protocol authoring to FDA submission, including SDTM mapping, ADaM dataset generation, and publication-ready reports. The platform integrates with internal SOPs and historical documents to provide a collaborative workspace with audit-ready version control. PhaseV reports having delivered ROI for over 45 pharma and biotech sponsors, with claims of reducing trial costs by up to 50% and increasing probability of success by over 30%.PR NewswirePhaseV Launches AI Conductor to Automate Protocol-to-Submission Clinical WorkflowsPhaseV launched an AI platform called AI Conductor designed to automate and optimize clinical development processes. The platform enhances trial design, data management, and regulatory compliance, supporting biopharma sponsors and CROs in conducting efficient clinical trials.ClinicalresearchnewsonlineSCOPE 2026: AI in Clinical Research Poised for Boom TimesAt the SCOPE 2026 event in Orlando, several companies announced new product launches, funding, and leadership appointments related to artificial intelligence (AI) in clinical research. These developments aim to reduce trial timelines and costs, with AI-enabled platforms introduced by Trialbee, ConcertAI, PhaseV, and Biorce, among others.